新辅助化疗后经口机器人手术与一期手术治疗局部晚期口咽癌:倾向性评分匹配分析
这项回顾性双中心研究比较了新辅助化疗(NAC)后经口机器人手术(TORS)与一期TORS治疗III-IV期口咽鳞状细胞癌(OPSCC)的疗效。300例患者中204例经1:1倾向性评分匹配,两组复发及无复发生存(RFS)、总生存(OS)、疾病特异性生存(DSS)均无显著差异;在NAC+TORS的p16阳性人群中,51%可免除辅助治疗,而一期手术组为16%(p < 0.001)。
要点
- NAC+TORS与一期TORS在复发及RFS、OS、DSS方面无显著差异。
- p16阳性者NAC+TORS组51%免除辅助治疗,一期手术组16%(p < 0.001)。
- NAC后病理危险因素减少,可能降低辅助治疗需求。
核心结论
- NAC后TORS治疗局部晚期OPSCC的生存结局不劣于一期手术,在p16阳性人群中可显著免除辅助治疗。
研究设计与样本
- 回顾性双中心研究,分析NAC+TORS与一期TORS患者,采用1:1倾向性评分匹配比较两组。
- 共300例III-IV期OPSCC患者,其中204例匹配后用于比较NAC+TORS与一期TORS。
主要发现
- 两组间复发及RFS、OS、DSS均无显著差异。
- NAC+TORS组p16阳性人群中51%可免除辅助治疗,一期手术组为16%(p < 0.001)。
- NAC后病理危险因素频率较低。
关键数值与推荐
- NAC+TORS组p16阳性人群辅助治疗免除率51% vs 一期手术组16%(p < 0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transoral robotic surgery (TORS) performed after neoadjuvant chemotherapy (NAC) is a promising treatment for advanced-stage oropharyngeal carcinoma (OPSCC) able to reduce the adjuvant therapy administration rate. METHODS: A retrospective bi-centric study was conducted to analyze NAC + TORS versus upfront TORS patients. A 1:1 propensity score matching was used to compare the two groups. RESULTS: Among the 300 patients with stage III-IV OPSCC, 204 patients were matched for comparing NAC + TORS versus upfront TORS. Between the two groups, no significant difference was observed in recurrences and in survival for RFS, OS, and DSS. In the NAC + TORS p16-positive population, adjuvant therapy could be spared in 51% versus 16% in the upfront surgery cohort (p < 0.001) due to the lower frequency of pathological risk factors after NAC. CONCLUSIONS: NAC followed by TORS for locoregionally advanced OPSCC demonstrated to achieve non-inferior survival outcomes to upfront surgery, while in the p16-positive population allowed to significantly spare adjuvant therapy.
引用
- Sampieri C, Cioccoloni E, Costantino A, et al. Neoadjuvant chemotherapy followed by transoral robotic surgery versus upfront surgery for locoregionally advanced oropharyngeal carcinoma: A propensity score matched analysis. Head Neck. 2024. PMID: 39087607. doi:10.1002/hed.27904
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。